Ionova Life Science
A biomedical company that leads technological innovation and benefits human health.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
$100m | Early VC | ||
| Total Funding | 000k | ||
Related Content
Ionova Life Science is a clinical-stage biotechnology company located in the Guangdong-Hong Kong-Macao Greater Bay Area of China, established in November 2016. The company was founded by Dr. Yongkui Sun, a scientist with over 20 years of experience in research and development at Merck Research Laboratories and a member of the US National Academy of Engineering. Dr. Sun's extensive background in the pharmaceutical industry underpins the company's core mission.
The firm concentrates on the development of a new generation of targeted immunotherapies for cancer treatment. Its operational strategy is centered on translating discoveries in basic biomedical research into novel drugs with distinct clinical advantages. Ionova's business model involves in-house drug discovery and development, supplemented by collaborations with academic and industrial partners through its research division, the Touchstone Translational Research Institute. The company's revenue generation is tied to the progression of its drug candidates through clinical trials and eventual commercialization, a long-term strategy typical of the biotechnology sector. This is supported by significant venture capital funding.
Ionova Life Science has built a robust pipeline of drug candidates aimed at combating cancers and addressing cancer resistance. A key focus area since its inception has been research into the tumor microenvironment and immunoregulation. The company's product development strategy combines immunotherapy with targeted therapy to create synergistic effects. One of its leading candidates, INV-1120, has entered Phase I clinical trials in the United States. The company has secured substantial funding to advance its portfolio, including a $17 million Series A in October 2019 and a $100 million financing round in August 2021, which supports the progression of its preclinical and clinical oncology candidates.
Keywords: clinical-stage biotechnology, cancer treatment, targeted immunotherapy, drug discovery, tumor microenvironment, immunoregulation, oncology pipeline, biopharmaceutical, cancer resistance, clinical trials, translational research, small molecule drugs, monoclonal antibody, venture capital-backed, oncology therapeutics, biomedical research, pharmaceutical development, cancer biology, China biotech, Guangdong-Hong Kong-Macao Greater Bay Area